Buy or sell Annexon Biosciences stock pre IPO via an EquityZen fund

EquityZen is a marketplace for shares of proven pre IPO tech companies

Annexon Biosciences Stock

Biotechnology company developing therapeutics for neurodegenerative and autoimmune disorders

Founded

2011

Notable Investors

Headquarters

South San Francisco CA, US

Total Funding

$154M

About Annexon Biosciences Stock

Annexon Biosciences is the development of therapeutic products that halt the progression of complement-mediated neurodegeneration (CMND).

Funding History

August 2011$1000K
December 2014$34.0M
June 2016$44.0M
December 2018$75.0M

Management

Chief Scientific Officer

Ted Yednock

Co-Founder

Arnon Rosenthal

President & Chief Executive Officer

Douglas Love

Other Companies

Logo
Atreca

Atreca develops a technology to identify the set of antibodies produced during an immune response, without prior knowledge of an antigen.

Logo
Caribou Biosciences

Caribou Biosciences is a biotechnology company in genome engineering. We develop technology-based solutions for cellular.

Logo
GoodRx

GoodRx believes prescription drugs should be affordable and convenient for everyone.

Logo
Nimbus Therapeutics

Nimbus Discovery is now Nimbus Therapeutics to reflect our transition into a clinical stage company.

EquityZen does not have an affiliation with, formal relationship with, or endorsement from Annexon Biosciences or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 70K+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo

Logo